Clinical Study
Testing a Study Drug BMS-986278 for People with Progressive Pulmonary Fibrosis
Progressive Pulmonary Fibrosis is a disease scarring the lungs causing shortness of breath. The disease worsens over time. This study will test a study drug called BMS-986278 to treat people with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen the be treated with BMS-986278 or a placebo. The placebo looks like the study drug but does not have the medication. Being in the study requires at least 13 in-person study visits at the study clinic for the first 52 weeks then every 12 weeks after up to 4 years. Medical tests will be done to track the health of participants.
For more information contact:
Cassie Larsen
cassie.larsen@hsc.utah.edu
18015815811
IRB#: IRB_00171171
| PI: Mary Beth Scholand
| Department: PULMONARY
| Approval Date: 2024-04-03 06:00:00
Specialties: Pulmonary
Who can participate?
Gender: All
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 21 years and older
- Diagnosis of Interstitial Lung Disease (a group of disorders that cause scarring of the lungs)
- If on pirfenidone or nintedanib medication, must be on a stable dose for at least the prior 90 days
- If not on pirfenidone or nintedanib medication, cannot have received either medication within the prior 28 days
- Must agree to use specific birth control
Exclusion Criteria:
- Diagnosis of Idiopathic Pulmonary Fibrosis
- Pregnant or breastfeeding, or have a positive pregnancy test during the study
- Positive urine test for abuse of drugs
Will I be paid for my time?
Yes